Compare Manulife Financial Corporation (MFC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Organon & Co. Common Stock — how do they compare? Manulife Financial Corporation trades at $42.93 (market cap $71.31B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Manulife Financial Corporation is far larger — about 19.7× Organon & Co. Common Stock's market cap, and Manulife Financial Corporation pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 120 Days and Organon & Co. Common Stock for 0 Days on average.
| MFC | OGN | |
|---|---|---|
Market Cap | $71.31B | $3.62B |
Volume | 1,535,090 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $44.77 | $13.81 |
52-Week Low | $31.64 | $5.70 |
Typical Hold Time | 120 Days | 0 Days |
Enterprise Value | $66.58B | $11.04B |
Dividend Yield | 3.15% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.10, up 0.56% today, with a neutral technical signal and bullish moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7% and a P/E of 16.73. Recent news includes a new Chief Marketing Officer appointment and strong institutional investments, such as Bank of America's $145.18 million stake.
The outlook is positive with analyst consensus at Buy (57.14%) and a price target of $34.24, though below the current price. Risks include competitive pressures and debt levels, but earnings beats and dividend payments support stability. Growth is driven by Asia expansion and reinsurance deals, yet valuation premiums may limit near-term upside.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
